367 related articles for article (PubMed ID: 27301022)
1. Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis.
Chollet A; Stigliani JL; Pasca MR; Mori G; Lherbet C; Constant P; Quémard A; Bernadou J; Pratviel G; Bernardes-Génisson V
Chem Biol Drug Des; 2016 Nov; 88(5):740-755. PubMed ID: 27301022
[TBL] [Abstract][Full Text] [Related]
2. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
4. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
6. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
Subba Rao G; Vijayakrishnan R; Kumar M
Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
[TBL] [Abstract][Full Text] [Related]
8. Identification of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors: A combined in-silico and in-vitro analysis.
Lone MY; Athar M; Gupta VK; Jha PC
J Mol Graph Model; 2017 Sep; 76():172-180. PubMed ID: 28734205
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis.
Molle V; Gulten G; Vilchèze C; Veyron-Churlet R; Zanella-Cléon I; Sacchettini JC; Jacobs WR; Kremer L
Mol Microbiol; 2010 Dec; 78(6):1591-605. PubMed ID: 21143326
[TBL] [Abstract][Full Text] [Related]
10. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
[TBL] [Abstract][Full Text] [Related]
11. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
12. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
Inturi B; Pujar GV; Purohit MN
Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
[TBL] [Abstract][Full Text] [Related]
14. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
[TBL] [Abstract][Full Text] [Related]
15. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
16. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
[TBL] [Abstract][Full Text] [Related]
17. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
Khan AM; Shawon J; Halim MA
J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
[TBL] [Abstract][Full Text] [Related]
18. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
